Ziel
We concur to the IMI on “Reclassification of SLE, connective tissue diseases and RA” call by presenting a proposal aimed at using the power of OMICs, and bioinformatics to identify new classifications for diseases known to share common pathophysiological mechanisms. Such knowledge has not been applied to individual patients, depriving them from potential benefits in terms of the use of new therapeutic agents that are being developed for one disease but cannot be applied in another due to current clinical classifications.
We will investigate individuals with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren’s syndrome (Sjs), rheumatoid arthritis (RA), primary antiphospholipid syndrome (PAPS) and mixed connective tissue disease (MCTD), jointly as systemic autoimmune diseases (SADs). We believe that there will be overlapping clusters of individuals across diseases that will share molecular features. To determine these clusters we will, study 2000 cases of SADs, and 600 healthy controls to identify molecular clusters and their cellular and clinical correlates. In addition, we will study kidney and skin biopsies to define the development of molecular markers with severe kidney disease or with skin fibrosis. In this way we will define systemic and tissue taxonomies. We will study complete as well as isolated peripheral blood mononuclear cells and subpopulations and in biopsies gene expression and epigenetic marks with a combination of array and next generation sequencing (NGS) strategies. These studies will define cellular counts and proportions and changes in gene expression related to specific cellular populations. We will also use NGS strategies to define the presence of risk alleles (HLA and non-HLA) in all individuals. The data will be complemented with the study of the presence of autoantibodies in serum (analyzed in a reference lab), and we will use metabolomics mass spectrometry and NMR approaches to analyze plasma and urine metabolites. We will also study exosomes in plasma and urine and identify their molecular profiles. Samples will be collected following strict protocols and appropriate patient selection. The bioinformatics and biostatistics approaches will be aimed at the analysis of clusters with unsupervised clustering algorithms and tools and cross-validation. We will also perform analyses to determine risk and predictive models analyzing the genetic and molecular data at different levels, leading to a highly productive study with two arms, one for basic research and one with clinical applications. Among the clinical applications we will have a new classification for groups of patients sharing molecular mechanisms of disease, biomarkers for disease progression and organ damage prediction, and we will develop assays that can be easily applied in the clinic. The resultant clinically applicable clusters will be then validated in a longitudinal, inception trial where newly recruited patients will be analyzed at baseline and at two different time points and define their clustering status or their evolution towards specific clusters.
We will gain completely novel information that will open new avenues of research and new possibilities of collaboration between the public Academy and the private Pharmaceutical sector by establishing the basis for new clinical trials with the potential to really benefit the patients.
Wissenschaftliches Gebiet
- medical and health sciencesclinical medicinerheumatology
- natural sciencesbiological sciencescell biology
- medical and health sciencesbasic medicineimmunologyautoimmune diseases
- natural scienceschemical sciencesanalytical chemistrymass spectrometry
- medical and health sciencesclinical medicinenephrologykidney diseases
Programm/Programme
Aufforderung zur Vorschlagseinreichung
IMI-JU-08-2012
Andere Projekte für diesen Aufruf anzeigen
Finanzierungsplan
JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)Koordinator
1070 Bruxelles / Brussel
Belgien
Auf der Karte ansehen
Beteiligte (28)
41092 Sevilla
Auf der Karte ansehen
28001 Madrid
Auf der Karte ansehen
4099 001 Porto
Auf der Karte ansehen
28006 Madrid
Auf der Karte ansehen
20122 Milano
Auf der Karte ansehen
08908 L'Hospitalet De Llobregat
Auf der Karte ansehen
Santander
Auf der Karte ansehen
08036 Barcelona
Auf der Karte ansehen
17177 Stockholm
Auf der Karte ansehen
3000 Leuven
Auf der Karte ansehen
50937 Koeln
Auf der Karte ansehen
30625 Hannover
Auf der Karte ansehen
1090 Wien
Auf der Karte ansehen
1228 Plan-les-Ouates
Auf der Karte ansehen
41071 Sevilla
Auf der Karte ansehen
2371 AGIOS DOMETIOS
Auf der Karte ansehen
18071 Granada
Auf der Karte ansehen
20122 Milano
Auf der Karte ansehen
1348 Louvain La Neuve
Auf der Karte ansehen
29238 BREST
Auf der Karte ansehen
1211 Geneve
Auf der Karte ansehen
6720 Szeged
Auf der Karte ansehen
Beteiligung beendet
10117 Berlin
Auf der Karte ansehen
51373 Leverkusen
Auf der Karte ansehen
92284 Courbevoie
Auf der Karte ansehen
94250 GENTILLY
Auf der Karte ansehen
RG21 4FA Basingstoke
Auf der Karte ansehen
10117 Berlin
Auf der Karte ansehen